DK3354649T3 - Oxaspiroderivat, fremstillingsmetode derfor og anvendelser deraf i lægemidler - Google Patents

Oxaspiroderivat, fremstillingsmetode derfor og anvendelser deraf i lægemidler Download PDF

Info

Publication number
DK3354649T3
DK3354649T3 DK16854888.1T DK16854888T DK3354649T3 DK 3354649 T3 DK3354649 T3 DK 3354649T3 DK 16854888 T DK16854888 T DK 16854888T DK 3354649 T3 DK3354649 T3 DK 3354649T3
Authority
DK
Denmark
Prior art keywords
oxaspiroder
pharmaceuticals
derivatives
applications
preparation
Prior art date
Application number
DK16854888.1T
Other languages
Danish (da)
English (en)
Inventor
Xin Li
Binqiang Feng
Yang Chen
Tao Liu
Feng He
Mingxun He
Weikang Tao
Piaoyang Sun
Original Assignee
Jiangsu Hengrui Medicine Co
Shanghai hengrui pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co, Shanghai hengrui pharmaceutical co ltd filed Critical Jiangsu Hengrui Medicine Co
Application granted granted Critical
Publication of DK3354649T3 publication Critical patent/DK3354649T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK16854888.1T 2015-10-15 2016-09-30 Oxaspiroderivat, fremstillingsmetode derfor og anvendelser deraf i lægemidler DK3354649T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510665328 2015-10-15
CN201511032876 2015-12-31
PCT/CN2016/101064 WO2017063509A1 (zh) 2015-10-15 2016-09-30 氧杂螺环类衍生物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
DK3354649T3 true DK3354649T3 (da) 2020-02-24

Family

ID=58517778

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16854888.1T DK3354649T3 (da) 2015-10-15 2016-09-30 Oxaspiroderivat, fremstillingsmetode derfor og anvendelser deraf i lægemidler

Country Status (16)

Country Link
US (1) US10442793B2 (enExample)
EP (1) EP3354649B1 (enExample)
JP (1) JP6824502B2 (enExample)
KR (1) KR102703513B1 (enExample)
CN (1) CN107001347B (enExample)
AU (1) AU2016339404B2 (enExample)
CA (1) CA3000761C (enExample)
DK (1) DK3354649T3 (enExample)
ES (1) ES2772689T3 (enExample)
HU (1) HUE048032T2 (enExample)
MX (1) MX382815B (enExample)
PL (1) PL3354649T3 (enExample)
PT (1) PT3354649T (enExample)
RU (1) RU2733373C2 (enExample)
TW (1) TWI727981B (enExample)
WO (1) WO2017063509A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX388643B (es) * 2017-04-14 2025-03-20 Jiangsu Hengrui Medicine Co Composicion farmaceutica que contiene agonista de mor y agonista de kor, y sus usos
EP3610875B1 (en) * 2017-04-14 2020-10-07 Jiangsu Hengrui Medicine Co., Ltd. Opioid receptor (mor) agonist salt, fumarate salt i crystal form thereof and preparation method thereof
CN108727347B (zh) * 2017-04-14 2020-06-16 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的晶型及其制备方法
CN109206417B (zh) * 2017-07-04 2023-01-03 四川海思科制药有限公司 阿片受体激动剂及其应用
US11072601B2 (en) 2017-09-18 2021-07-27 Shanghai Synergy Pharmaceutical Sciences Co., Ltd. μ-opioid receptor agonist and preparation method therefor and use thereof in field of medicine
WO2019062804A1 (zh) 2017-09-28 2019-04-04 江苏恒瑞医药股份有限公司 一种氧杂螺环类衍生物的制备方法及其中间体
AU2018349930A1 (en) * 2017-10-13 2020-04-16 Shandong Luye Pharmaceutical Co., Ltd. 2,6-dioxaspiro (4,5) decane derivatives and preparation method therefor and pharmaceutical applications thereof
JP2021505547A (ja) * 2017-12-06 2021-02-18 江蘇恒瑞医薬股▲ふん▼有限公司 疼痛を治療するための薬物の製造におけるmorアゴニストと組み合わせたkorアゴニストの使用
CN111836807A (zh) * 2018-04-28 2020-10-27 四川科伦博泰生物医药股份有限公司 氧杂螺环类化合物及其制备方法和用途
CN108424372B (zh) * 2018-05-11 2021-08-10 浙江华贝药业有限责任公司 2,2,2-三氟-n-[(s)-4-羰基四氢萘-1-基]-乙酰胺的纯化工艺
CN111163778B (zh) * 2018-05-14 2023-01-24 江苏恒瑞医药股份有限公司 一种mor受体激动剂药物组合物
CN108707086B (zh) * 2018-05-15 2021-08-10 浙江华贝药业有限责任公司 一种(1s,4s)-n-(4-羟基四氢萘-1-基)叔丁氧基碳酰胺的纯化工艺
WO2020073985A1 (zh) * 2018-10-12 2020-04-16 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
WO2020073984A1 (zh) * 2018-10-12 2020-04-16 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
CN112334465B (zh) * 2019-01-17 2024-06-11 上海海雁医药科技有限公司 三环取代的氧杂螺环衍生物、其制法与医药上的用途
CN111662284B (zh) * 2019-03-06 2021-08-10 上海海雁医药科技有限公司 双杂环取代的氧杂螺环衍生物、其制法与医药上的用途
WO2021027304A1 (zh) * 2019-08-14 2021-02-18 上海海雁医药科技有限公司 镇痛化合物、其制法与医药上的用途
EP4092031A4 (en) * 2020-01-17 2024-02-21 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. AZABICYCLIC SUBSTITUTED OXASPIRO DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF AND ITS MEDICAL USE
CN118221680A (zh) 2020-01-17 2024-06-21 上海海雁医药科技有限公司 光学纯的氧杂螺环取代的吡咯并吡唑衍生物、其制法与医药上的用途
CN113214264B (zh) * 2020-01-21 2022-08-09 上海海雁医药科技有限公司 二氢吡咯并五元杂芳基取代的氧杂螺环衍生物、其制法与医药上的用途
JP7781064B2 (ja) 2020-01-22 2025-12-05 江蘇恒瑞医薬股▲ふん▼有限公司 抗trop-2抗体-エキサテカン類似体複合体及びその医薬用途
CN114075141B (zh) * 2020-08-20 2025-02-25 上海致根医药科技有限公司 阿片受体“偏向性”配体、其制备方法及其在医药上的应用
CN114539257B (zh) * 2020-11-24 2023-08-11 江苏恒瑞医药股份有限公司 嘧啶二酮类螺环衍生物、其制备方法及其在医药上的应用
JP7751645B2 (ja) 2020-12-29 2025-10-08 上海海雁医薬科技有限公司 オキシスピロ環置換ピロロピラゾール誘導体及びその中間体並びにその調製方法
WO2023284788A1 (zh) 2021-07-13 2023-01-19 上海海雁医药科技有限公司 Mor受体激动剂的药学上可接受的盐、其多晶型物及其用途
WO2023011422A1 (zh) * 2021-08-02 2023-02-09 上海枢境生物科技有限公司 氧杂螺环类衍生物、制备方法及其用途
CN117263956A (zh) * 2022-01-19 2023-12-22 天地恒一制药股份有限公司 阿片受体激动剂及其制备方法和用途
CN116589451B (zh) * 2022-02-11 2024-07-09 成都硕德药业有限公司 一种6-氧杂螺[4,5]癸烷类化合物的新晶型、用途及其制备方法
CN117624138A (zh) * 2022-08-29 2024-03-01 江苏恒瑞医药股份有限公司 一种氧杂螺环类衍生物的可药用盐、晶型及制备方法
CN119894904B (zh) * 2022-09-27 2025-12-30 上海枢境生物科技有限公司 一种含螺环类衍生物的盐、晶型及其制备方法和应用
KR20250137614A (ko) 2023-01-18 2025-09-18 상하이 센후이 메디슨 컴퍼니 리미티드 테트라히드로-1-나프틸아민 및 이의 유도체의 제조 방법
WO2026026772A1 (zh) * 2024-07-30 2026-02-05 上海枢境生物科技有限公司 氧杂螺环类衍生物的富马酸盐晶型及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2160534B1 (es) 1999-12-30 2002-04-16 Vita Invest Sa Nuevos esteres derivados de (rr,ss)-2-hidroxibenzoato de 3-(2-dimetilaminometil-1-hidroxiciclohexil) fenilo.
DE10044649A1 (de) 2000-09-08 2002-07-04 Gruenenthal Gmbh Substituierte 4-Phenyl-1-(1-phenyl-cyclohexyl)-1,2,3,6-tetrahydropyridine
DE102006033109A1 (de) * 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
US7999107B2 (en) * 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
US20090028873A1 (en) 2007-07-27 2009-01-29 Auspex Pharmaceuticals, Inc. Substituted cyclohexanols
AU2009308769B2 (en) 2008-10-31 2015-03-12 Pain Therapeutics, Inc. Filamin A-binding anti-inflammatory analgesic
CN102741258B (zh) 2009-06-17 2015-09-30 德州大学体系董事会 作为分离剂的环果聚糖的组成物及方法
SI2688403T1 (sl) * 2011-03-23 2017-08-31 Trevena, Inc. Ligandi opioidnih receptorjev in metode uporabe in izdelave istega
CN104159902B (zh) 2011-12-12 2016-05-04 格吕伦塔尔有限公司 制备(1r,4r)-6’-氟-(N,N-二甲基-和N-甲基)-4-苯基-4’,9’-二氢-3’H-螺[环己烷-1,1’-吡喃并[3,4,b]吲哚]-4-胺的方法
PL2880037T3 (pl) 2012-08-03 2019-07-31 Johnson Matthey Public Limited Company Sposób wytwarzania oksykodonu
RS55593B1 (sr) 2012-11-13 2017-06-30 Array Biopharma Inc Jedinjenja biciklične uree, tiouree, guanidina i cijanoguanidina korisna za lečenje bola

Also Published As

Publication number Publication date
TWI727981B (zh) 2021-05-21
CN107001347B (zh) 2019-09-24
RU2018115569A (ru) 2019-11-18
HUE048032T2 (hu) 2020-05-28
AU2016339404A1 (en) 2018-05-24
US10442793B2 (en) 2019-10-15
TW201718558A (zh) 2017-06-01
CA3000761C (en) 2024-02-13
JP6824502B2 (ja) 2021-02-03
AU2016339404B2 (en) 2020-08-27
US20180297988A1 (en) 2018-10-18
RU2018115569A3 (enExample) 2020-01-20
WO2017063509A1 (zh) 2017-04-20
KR102703513B1 (ko) 2024-09-06
CA3000761A1 (en) 2017-04-20
MX382815B (es) 2025-03-12
EP3354649B1 (en) 2019-12-04
RU2733373C2 (ru) 2020-10-01
EP3354649A1 (en) 2018-08-01
BR112018006448A2 (pt) 2018-10-16
JP2018534257A (ja) 2018-11-22
PT3354649T (pt) 2020-02-03
EP3354649A4 (en) 2018-08-08
ES2772689T3 (es) 2020-07-08
PL3354649T3 (pl) 2020-07-27
CN107001347A (zh) 2017-08-01
MX2018004175A (es) 2018-06-06
KR20180063251A (ko) 2018-06-11

Similar Documents

Publication Publication Date Title
DK3354649T3 (da) Oxaspiroderivat, fremstillingsmetode derfor og anvendelser deraf i lægemidler
IL289276A (en) Treprostinil derivatives and compositions and uses thereof
DK3378859T3 (da) Benzofuranderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i medicin
DK3486242T3 (da) Oxopicolinamidderivat, fremgangsmåde til fremstilling deraf og farmaceutisk anvendelse deraf
DK3453707T3 (da) Benzazepinderivat, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf
DK3256468T3 (da) Tricykliske forbindelser og anvendelser deraf i lægemidler
DK4000608T3 (da) Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf
DK3331894T3 (da) Nicotinamidmononukleotidderivater og anvendelser deraf
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3354282T3 (da) Glycan-terapeutiske midler og relaterede fremgangsmåder deraf
PL3319813T3 (pl) Dokumenty zabezpieczone i urządzenia zabezpieczające oraz sposób ich wytwarzania
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3559000T3 (da) Benzimidazol-derivater, fremgangsmåder til fremstilling og anvendelser deraf
DK3214081T3 (da) Isoindolinderivat, mellemprodukt, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf
DK3236991T3 (da) Fgf21-derivater og anvendelser deraf
IL246987B (en) Herteroaryl amides, compositions comprising same and uses thereof
DK3233111T3 (da) Farmaceutisk sammensætning, der omfatter plasminogen, og anvendelser deraf
DK3305310T3 (da) Onkolytisk virusformulering og fremgangsmåde til fremstilling deraf
DK3404024T3 (da) Quinazolinonderivat, fremgangsmåde til fremstilling deraf, farmaceutisk sammensætning og anvendelser
FI20155621A7 (fi) Menetelmä ja tuote
DK3263565T3 (da) Cyklisk aminderivat og farmaceutisk anvendelse deraf
SI3064498T1 (sl) Derivati pirazolopirimidona ali pirolotriazona, postopki priprave le-teh in farmacevtske uporabe le-teh
DK3271453T3 (da) Glycosylerede lysosomale proteiner, fremgangsmåde til fremstilling og anvendelser
DK3212166T3 (da) Varme-steriliseret formulering omfattende chitosan og fremgangsmåde til fremstilling deraf
DK3236934T3 (da) Farmaceutisk sammensætning, fremstilling og anvendelser deraf